Biotech company, CSL (ASX:CSL) has reported its net profit after tax (NPAT) increased 10 per cent to $1.16 billion for the first half of 2019 when compared to the prior corresponding period.
Sales revenue strengthened over the six month period, and lifted 11 per cent on the same time last year to almost $4.5 billion.
Its earnings before interest and tax (EBIT) increased by 6 per cent on the prior year, to $1.6 billion.
The company declared an interim dividend of 85 cents per share up 8 per cent on the prior corresponding period.
CSL expects its FY19 net profit after tax guidance to be at the upper end of its previously provided range of $1.88 to $1.95 billion.
The company says it's a solid result and particularly pleasing given it follows a very strong comparative period.
(Results are in constant currency terms).
Shares in CSL (ASX:CSL) are trading 2.5 per cent lower to $188.83.